CPSE:VIRO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ViroGates A/S, a medical technology company, provides various products to measure soluble urokinase plasminogen activating receptor in blood. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has ViroGates's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VIRO has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-5.6%

VIRO

4.4%

DK Medical Equipment

2.5%

DK Market


1 Year Return

61.2%

VIRO

29.5%

DK Medical Equipment

29.3%

DK Market

Return vs Industry: VIRO exceeded the Danish Medical Equipment industry which returned 25.6% over the past year.

Return vs Market: VIRO exceeded the Danish Market which returned 26.5% over the past year.


Shareholder returns

VIROIndustryMarket
7 Day-5.6%4.4%2.5%
30 Day-4.8%0.6%3.8%
90 Day-8.5%1.5%9.0%
1 Year61.2%61.2%31.1%29.5%31.8%29.3%
3 Yearn/a83.9%76.4%49.7%37.9%
5 Yearn/a154.9%134.5%69.8%48.3%

Price Volatility Vs. Market

How volatile is ViroGates's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ViroGates undervalued compared to its fair value and its price relative to the market?

4.7x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VIRO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VIRO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VIRO is unprofitable, so we can't compare its PE Ratio to the DK Medical Equipment industry average.

PE vs Market: VIRO is unprofitable, so we can't compare its PE Ratio to the Danish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VIRO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VIRO is good value based on its PB Ratio (4.7x) compared to the DK Medical Equipment industry average (10.1x).


Next Steps

Future Growth

How is ViroGates forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ViroGates has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has ViroGates performed over the past 5 years?

-31.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VIRO is currently unprofitable.

Growing Profit Margin: VIRO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VIRO is unprofitable, and losses have increased over the past 5 years at a rate of 31.3% per year.

Accelerating Growth: Unable to compare VIRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VIRO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-51.7%).


Return on Equity

High ROE: VIRO has a negative Return on Equity (-53.96%), as it is currently unprofitable.


Next Steps

Financial Health

How is ViroGates's financial position?


Financial Position Analysis

Short Term Liabilities: VIRO's short term assets (DKK43.1M) exceed its short term liabilities (DKK4.2M).

Long Term Liabilities: VIRO's short term assets (DKK43.1M) exceed its long term liabilities (DKK1,000.0).


Debt to Equity History and Analysis

Debt Level: VIRO is debt free.

Reducing Debt: VIRO had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VIRO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VIRO has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 33.4% each year.


Next Steps

Dividend

What is ViroGates's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VIRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VIRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VIRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VIRO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VIRO's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Jakob Knudsen (52 yo)

9.42yrs

Tenure

Mr. Jakob Knudsen has been Director at ExpreS2ion Biotech Holding AB (publ) since April 19, 2017. Mr. Knudsen has been the Chief Executive Officer at ViroGates A/S since April 2011. Mr. Knudsen serves as a ...


Leadership Team

NamePositionTenureCompensationOwnership
Jakob Knudsen
Chief Executive Officer9.42yrsno data0.16%
DKK 290.5k
Jesper Eugen-Olsen
Co-Founder & Chief Scientific Officer20.67yrsno data9.86%
DKK 18.3m
Mark Christian da Silva
Chief Financial Officer0.92yrno datano data
May Dyvelkov
Vice President of Accounting0.92yrno data0.048%
DKK 88.6k
Thomas Krarup
Vice President of Global Sales & Marketing2.5yrsno data0.019%
DKK 36.0k

2.5yrs

Average Tenure

57yo

Average Age

Experienced Management: VIRO's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lars Krogsgaard
Director4.42yrsno data10.44%
DKK 19.4m
Jørgen Thorball
Independent Director19.67yrsno data0.33%
DKK 607.1k
Peter Aaby
Scientific Advisorno datano datano data
Bernd Uder
Independent Non-Executive Director5.5yrsno datano data
Lars Kongsbak
Independent Chairman of the Board5.5yrsno data0.11%
DKK 206.3k
Knut Borch-Johnsen
Scientific Advisor13.67yrsno datano data

5.5yrs

Average Tenure

59yo

Average Age

Experienced Board: VIRO's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.


Top Shareholders

Company Information

ViroGates A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ViroGates A/S
  • Ticker: VIRO
  • Exchange: CPSE
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr.185.809m
  • Shares outstanding: 3.12m
  • Website: https://www.virogates.com

Number of Employees


Location

  • ViroGates A/S
  • Blokken 45
  • Birkerød
  • Capital Region of Denmark
  • 3460
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VIROCPSE (OMX Nordic Exchange Copenhagen)YesShare CapitalDKDKKJun 2018

Biography

ViroGates A/S, a medical technology company, provides various products to measure soluble urokinase plasminogen activating receptor in blood. The company develops and markets suPARnostic, a blood test used ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/29 22:00
End of Day Share Price2020/09/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.